These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35134966)

  • 1. Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
    Sun Z; Lan Y; Liang S; Wang J; Ni M; Zhang X; Yu F; Chen M; Zhang H; Yan L; Cai W; Lan G; Ma Y; Zhang F
    J Antimicrob Chemother; 2022 Mar; 77(4):1119-1124. PubMed ID: 35134966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
    Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
    J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRF08_BC subtype is more prone to ART failure and new-generation NNRTI-resistance under long-term first-line ART.
    Wu M; Dong Y; Zeng L; Lin Y; Yao L; Zhang Y; Sun W; Sun J; Wang Q; Yuan D; Xiao H
    Int J Antimicrob Agents; 2024 Aug; 64(2):107215. PubMed ID: 38795930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
    Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.
    Reddy N; Papathanasopoulos M; Steegen K; Basson AE
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
    Soulie C; Santoro MM; Charpentier C; Storto A; Paraskevis D; Di Carlo D; Gennari W; Sterrantino G; Zazzi M; Perno CF; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG
    J Antimicrob Chemother; 2019 Mar; 74(3):614-617. PubMed ID: 30476106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A;
    Int J Antimicrob Agents; 2023 Mar; 61(3):106737. PubMed ID: 36708743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
    Steegen K; Moorhouse M; Wensing AM; Venter WD; Hans L
    J Int AIDS Soc; 2021 May; 24(5):e25706. PubMed ID: 33943000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
    Rhee SY; Schapiro JM; Saladini F; Zazzi M; Khoo S; Shafer RW
    AIDS Res Ther; 2023 Feb; 20(1):8. PubMed ID: 36750835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.
    Xie YN; Zhu FX; Zhong YT; Chen YT; Gao Q; Lai XL; Liu JJ; Huang DD; Zhang YN; Chen X
    J Antimicrob Chemother; 2021 Oct; 76(11):2975-2982. PubMed ID: 34402512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021.
    Zhang M; Ma Y; Wang Z; Wang G; Wang Q; Li X; Lin F; Zhang C
    Virulence; 2024 Dec; 15(1):2373105. PubMed ID: 38934465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
    Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H
    BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
    Liu L; Dong A; Liao L; Feng Y; Shao Y; Liang S; Ruan Y; Xing H
    Curr HIV Res; 2019; 17(6):441-451. PubMed ID: 31778107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
    Guerrero-Beltrán C; Martínez-Sanz J; Álvarez M; Olalla J; García-Álvarez M; Iribarren JA; Masiá M; Montero M; García-Bujalance S; Blanco JR; Rivero M; García-Fraile LJ; Espinosa N; Rodríguez C; Aguilera A; Vidal-Ampurdanes MC; Martínez M; Iborra A; Imaz A; Gómez-Sirvent JL; Peraire J; Portilla J; Caballero E; Alejos B; García F; Moreno S;
    J Antimicrob Chemother; 2020 May; 75(5):1294-1300. PubMed ID: 32030406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.